2023
The role of routine biopsy of the background liver in the management of hepatocellular carcinoma
Lee S, Ahmed M, Taddei T, Jain D. The role of routine biopsy of the background liver in the management of hepatocellular carcinoma. Human Pathology 2023, 138: 18-23. PMID: 37236406, DOI: 10.1016/j.humpath.2023.05.009.Peer-Reviewed Original ResearchConceptsLiver biopsyEarly HCC stagesHepatocellular carcinoma managementLarge university hospitalSeparate biopsiesCirrhosis statusClinical characteristicsClinical suspicionMedian ageEarly diseasePathology databaseRoutine biopsyHCC stageBiopsy resultsHCC patientsParenchymal findingsUniversity HospitalBackground liverHepatocellular carcinomaNontumoral liverHCC biopsiesBiopsyPatientsCirrhosisLiver
2022
Invasive Fungal Infections Are Underdiagnosed in Hospitalized Patients With Decompensated Cirrhosis: An Autopsy Study
SAFFO S, JAIN D, SANCHEZ H, GARCIA-TSAO G. Invasive Fungal Infections Are Underdiagnosed in Hospitalized Patients With Decompensated Cirrhosis: An Autopsy Study. Gastro Hep Advances 2022, 1: 803-806. PMID: 36160304, PMCID: PMC9497452, DOI: 10.1016/j.gastha.2022.05.015.Peer-Reviewed Original Research
2021
Interobserver agreement of estimating the extent of intestinal metaplasia in patients with chronic atrophic gastritis
Lerch JM, Pai RK, Brown I, Gill AJ, Jain D, Kővári B, Kushima R, Sheahan K, Slavik T, Srivastava A, Lauwers GY, Langner C. Interobserver agreement of estimating the extent of intestinal metaplasia in patients with chronic atrophic gastritis. Virchows Archiv 2021, 480: 1277-1281. PMID: 34904185, PMCID: PMC9184363, DOI: 10.1007/s00428-021-03245-9.Peer-Reviewed Original ResearchConceptsGastric intestinal metaplasiaChronic atrophic gastritisIntraclass correlation coefficientInterobserver agreementAtrophic gastritisIntestinal metaplasiaExtensive gastric intestinal metaplasiaAlcian blue-periodic acid SchiffExpert gastrointestinal pathologistsHigh interobserver agreementLow diagnostic accuracyMetaplastic epitheliumAntrum biopsiesGastrointestinal pathologistsGastric cancerDiagnostic accuracyAcid-SchiffAB-PASExpert pathologistsSpearman correlationGastritisMetaplasiaPatientsPathologistsClinicopathological significance of neutrophil-rich colorectal carcinoma
Rottmann BG, Patel N, Ahmed M, Deng Y, Ciarleglio M, Vyas M, Jain D, Zhang X. Clinicopathological significance of neutrophil-rich colorectal carcinoma. Journal Of Clinical Pathology 2021, 76: 34-39. PMID: 34312298, PMCID: PMC10910606, DOI: 10.1136/jclinpath-2021-207702.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalColorectal carcinomaHistological gradeTumor locationRight-sided tumor locationTumor cellsDNA mismatch repair (MMR) statusIndependent risk factorKaplan-Meier analysisHigh histological gradeAdvanced TNM stageMismatch repair statusPrognostic significanceCRC casesClinicopathological significanceTNM stageMetastasis stagePatient prognosisRisk factorsClinicopathological parametersMultivariate analysisRepair statusPatientsCarcinomaHigh ratePediatric Hepatocellular Adenomas
Pacheco MC, Torbenson MS, Wu TT, Kakar S, Jain D, Yeh MM. Pediatric Hepatocellular Adenomas. The American Journal Of Surgical Pathology 2021, 45: 1641-1647. PMID: 34148984, PMCID: PMC8608351, DOI: 10.1097/pas.0000000000001763.Peer-Reviewed Original ResearchConceptsHepatocellular adenomaPrepubescent groupPediatric patientsNonsyndromic groupΒ-cateninAdenoma subtypesImmunohistochemical staining profileHepatocellular adenoma subtypesPostpubescent groupClinical characteristicsUnclassified subtypeClinical historySyndromic groupsImmunohistochemical stainingPatientsType adenomasAdenomasSyndromeAge groupsLarger studyStaining profileSubtypesGreater percentageGroupLanguage search
2020
Hepatocellular neoplasms arising in genetic metabolic disorders: steatosis is common in both the tumor and background liver
Cheng L, Jain D, Kakar S, Torbenson MS, Wu TT, Yeh MM. Hepatocellular neoplasms arising in genetic metabolic disorders: steatosis is common in both the tumor and background liver. Human Pathology 2020, 108: 93-99. PMID: 33245984, DOI: 10.1016/j.humpath.2020.11.012.Peer-Reviewed Original ResearchConceptsGenetic metabolic disordersMetabolic disordersHepatocellular neoplasmsBackground liverType 1Ornithine carbamyl transferase deficiencyRare genetic metabolic disorderRare case reportBackground liver parenchymaGlycogen storage disease type 1Hereditary tyrosinemia type 1Disease type 1Tyrosinemia type 1Younger patientsRetrospective studyCase reportCommon findingLiver parenchymaSteatosisTransferase deficiencyPathological characterizationNeoplasmsTumorsDisordersPatients
2019
Etiology of cirrhosis in the young
Olave MC, Gurung A, Mistry PK, Kakar S, Yeh M, Xu M, Wu TT, Torbenson M, Jain D. Etiology of cirrhosis in the young. Human Pathology 2019, 96: 96-103. PMID: 31698008, DOI: 10.1016/j.humpath.2019.09.015.Peer-Reviewed Original ResearchConceptsEtiology of cirrhosisCommon causeCryptogenic cirrhosisViral hepatitidesAge groupsMulti-institutional retrospective studyYears age group childrenIncidence of cirrhosisCause of cirrhosisFatty liver diseaseDiagnosis of cirrhosisAge group childrenCongenital cholestatic diseasesClinical chartsYounger patientsLiver diseasePathology databaseRetrospective studyCholestatic diseasePathology reportsCirrhosisMetabolic disordersPatientsScant dataYoung adultsCryptogenic cirrhosis: Old and new perspectives in the era of molecular and genomic medicine
Nalbantoglu I, Jain D. Cryptogenic cirrhosis: Old and new perspectives in the era of molecular and genomic medicine. Seminars In Diagnostic Pathology 2019, 36: 389-394. PMID: 31395291, DOI: 10.1053/j.semdp.2019.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCryptogenic cirrhosisCC casesLiver diseaseUnknown etiologyMain histologic findingsPossible genetic counselingChronic liver diseaseWhole-exome sequencingCirrhosis casesPediatric patientsTransplant eligibilityHistologic findingsHistologic patternPotential etiologiesHistologic examinationHistologic characterizationGenetic testingEtiologyPatientsExome sequencingDiagnostic abilityGenetic counselingGenetic alterationsDiagnosisNew disorderProinsulin Expressing Neuroendocrine Tumors of the Pancreas
Celli R, Tang LH, Cai G, Freedman-Weiss M, Colunga M, Salem RR, Majumdar S, Jain D. Proinsulin Expressing Neuroendocrine Tumors of the Pancreas. Pancreas 2019, 48: 55-59. PMID: 30451800, DOI: 10.1097/mpa.0000000000001196.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsAvailable clinicopathologic dataIHC-negative tumorsSurgical oncology centersNormal insulin levelsIHC-positive tumorsSerum proinsulinClinicopathologic featuresPNET patientsClinicopathologic dataHypoglycemic patientsInsulin levelsProspective studyOncology centersSerum glucoseSuch tumorsClinical significanceInsulin immunohistochemistryRare casePatientsImmunohistochemistryProinsulinomaTumorsInsulinoma
2018
Histologic features of autoimmune hepatitis: a critical appraisal
Gurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal. Human Pathology 2018, 82: 51-60. PMID: 30041025, DOI: 10.1016/j.humpath.2018.07.014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBiopsyChildChild, PreschoolDatabases, FactualEmperipolesisFemaleHepatitis C, ChronicHepatitis, AutoimmuneHepatocytesHumansKupffer CellsLiverLiver CirrhosisLymphocytesMaleMiddle AgedPlasma CellsPredictive Value of TestsReproducibility of ResultsRetrospective StudiesSeverity of Illness IndexYoung AdultConceptsProminent plasma cellsAutoimmune hepatitisHistologic featuresPlasma cellsInflammatory gradePortal tractsScoring systemInitiation of therapySeverity of hepatitisDifferent control groupsChronic hepatitisHepatitis CFibrosis stageStudy groupDisease processHepatitisControl groupHyaline globulesFurther studiesPatientsTractCritical appraisalCellsGradeTypical featuresPrototheca zopfii Colitis in Inherited CARD9 Deficiency
Sari S, Dalgic B, Muehlenbachs A, DeLeon-Carnes M, Goldsmith CS, Ekinci O, Jain D, Keating MK, Vilarinho S. Prototheca zopfii Colitis in Inherited CARD9 Deficiency. The Journal Of Infectious Diseases 2018, 218: 485-489. PMID: 29659908, PMCID: PMC6049027, DOI: 10.1093/infdis/jiy198.Peer-Reviewed Original ResearchConceptsCARD9 deficiencyInherited CARD9 DeficiencySpecific immune defectsAbdominal painImmune defectsBloody diarrheaImmunocompromised individualsExome sequencingHuman protothecosisConsanguineous unionsProtothecosisNew mechanistic insightsFrameshift mutationDeficiencyPancolitisColitisPainDiarrheaPatientsPrototheca zopfiiImmunodeficiencyCARD9InfectionImmunityMonthsTranslocation of a gut pathobiont drives autoimmunity in mice and humans
Vieira S, Hiltensperger M, Kumar V, Zegarra-Ruiz D, Dehner C, Khan N, Costa FRC, Tiniakou E, Greiling T, Ruff W, Barbieri A, Kriegel C, Mehta SS, Knight JR, Jain D, Goodman AL, Kriegel MA. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 2018, 359: 1156-1161. PMID: 29590047, PMCID: PMC5959731, DOI: 10.1126/science.aar7201.Peer-Reviewed Original ResearchConceptsGut pathobiontAutoimmune-prone miceMurine findingsIntramuscular vaccinePathogenic autoantibodiesLiver biopsyAutoimmune responseAutoimmune patientsAntibiotic treatmentT cellsImmune diseasesAutoimmunitySusceptible humansPathobiontsSystemic tissuesHuman hepatocytesAutoantibodiesMortalityMiceCocultureHepatocytesGenetic backgroundTissueBiopsyPatients
2017
A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors
Murtha TD, Lupsa BC, Majumdar S, Jain D, Salem RR. A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors. Journal Of Gastrointestinal Surgery 2017, 21: 1335-1341. PMID: 28510792, DOI: 10.1007/s11605-017-3428-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsSystematic reviewRare pancreatic neuroendocrine tumorYale-New Haven HospitalMajority of patientsMedian tumor diameterLower insulin levelsBiomedical databases PubMedNew Haven HospitalSymptomatic hypoglycemiaMost patientsFemale predominanceTumor diameterClinicopathologic featuresInsulin levelsUncommon diseaseMean ageOvid MEDLINEHormonal levelsDatabases PubMedPatientsProinsulinomaHormone productionTumorsMassive Gastric Juvenile Polyposis
Lawless ME, Toweill DL, Jewell KD, Jain D, Lamps L, Krasinskas AM, Swanson PE, Upton MP, Yeh MM. Massive Gastric Juvenile Polyposis. American Journal Of Clinical Pathology 2017, 147: 390-390. PMID: 28340255, DOI: 10.1093/ajcp/aqx015.Peer-Reviewed Original ResearchConceptsGastric juvenile polyposisJuvenile polyposisJuvenile polypsMixed inflammatory infiltrateHigh-grade dysplasiaJuvenile polyposis syndromeAncillary diagnostic testsIntramucosal adenocarcinomaInflammatory infiltrateSecond patientSevere bleedingClinicopathologic featuresIntraepithelial neoplasiaEdematous stromaSevere dysplasiaPolyposis syndromeColumnar epitheliumPolyposisAdenocarcinomaPatientsDiagnostic testsStomachPolypsDysplasiaHypoalbuminemia
2016
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. Journal Of Clinical Oncology 2016, 35: 446-464. PMID: 28129524, DOI: 10.1200/jco.2016.69.4836.Peer-Reviewed Original ResearchConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical OncologyAmerican SocietyClinical decisionClinical pathologyAmerican PathologistsAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapyHER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Archives Of Pathology & Laboratory Medicine 2016, 140: 1345-1363. PMID: 27841667, DOI: 10.5858/arpa.2016-0331-cp.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiomarkers, TumorClinical Decision-MakingCombined Modality TherapyDecision TreesDiagnosis, DifferentialEsophageal NeoplasmsEvidence-Based MedicineHumansMedical OncologyMolecular Diagnostic TechniquesMolecular Targeted TherapyMutationNeoplasm GradingNeoplasm StagingPathology, ClinicalReceptor, ErbB-2Societies, MedicalStomach NeoplasmsSystematic Reviews as TopicUnited StatesConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical OncologyAmerican SocietyClinical decisionClinical pathologyAmerican PathologistsAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapyHER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma. American Journal Of Clinical Pathology 2016, 146: 647-669. PMID: 28077399, PMCID: PMC6272805, DOI: 10.1093/ajcp/aqw206.Peer-Reviewed Original ResearchConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical decisionAmerican SocietyAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingClinical OncologyTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapyClinical pathologyAmerican PathologistsRecurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension
Vilarinho S, Sari S, Yilmaz G, Stiegler AL, Boggon TJ, Jain D, Akyol G, Dalgic B, Günel M, Lifton RP. Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension. Hepatology 2016, 63: 1977-1986. PMID: 26874653, PMCID: PMC4874872, DOI: 10.1002/hep.28499.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmino Acid SequenceAnimalsCattleChildChild, PreschoolDNA Mutational AnalysisDogsFemaleGenes, RecessiveHomozygoteHumansHypertension, PortalInfantLiver FailureMaleMolecular Sequence DataPedigreePhosphotransferases (Alcohol Group Acceptor)Principal Component AnalysisRatsYoung AdultConceptsIdiopathic noncirrhotic portal hypertensionNoncirrhotic portal hypertensionPortal hypertensionHuman immunodeficiency viral infectionNoncirrhotic liver diseaseStable portal hypertensionSubset of patientsTreatment of patientsNucleoside analog didanosineLiver failureIndeterminate etiologyLiver diseaseHypertensionKinase levelsNew genetic testsViral infectionMechanisms mediatingDGUOK deficiencyPhenotypic spectrumSpecific causesDeoxyguanosine kinaseExome sequencingPatientsConsanguineous familyFunction mutationsVaried autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells
Monestime G, Borger DK, Kim J, Lopez G, Allgaeuer M, Jain D, Vortmeyer A, Wang HW, Sidransky E. Varied autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells. Molecular Genetics And Metabolism 2016, 118: 55-59. PMID: 26992326, DOI: 10.1016/j.ymgme.2016.02.008.Peer-Reviewed Original ResearchConceptsAutopsy findingsGaucher diseaseDose/durationEnzyme replacement therapySpleen statusPathological findingsReplacement therapyDisease burdenPathological studiesGaucher cellsPatientsHematological symptomsExtensive involvementTherapyParkinsonismDiseaseMultiple tissuesComplete absenceFindingsAutopsiesSymptomsPathologyBiomarkersCareHost factors are dominant in the development of post-liver transplant non-alcoholic steatohepatitis
Boga S, Munoz-Abraham AS, Rodriguez-Davalos MI, Emre SH, Jain D, Schilsky ML. Host factors are dominant in the development of post-liver transplant non-alcoholic steatohepatitis. World Journal Of Hepatology 2016, 8: 659-664. PMID: 27239259, PMCID: PMC4876289, DOI: 10.4254/wjh.v8.i15.659.Peer-Reviewed Original ResearchNon-alcoholic fatty liver diseaseNon-alcoholic steatohepatitisLiver transplantationDonor organsPathogenesis of NAFLDDevelopment of NASHHost factorsSame deceased donorOrthotopic liver transplantationFatty liver diseaseGraft injuryLiver allograftsLiver graftsDeceased donorsLiver diseaseGenetic factorsRole of recipientSteatohepatitisTransplantationRecipientsOrgansSLTUnique modelAllograftsPatients